Download PDF
Der Klinikarzt 2014; 43(S 02): 30-33
DOI: 10.1055/s-0034-1396592
Schwerpunkt
© Georg Thieme Verlag Stuttgart · New York

Urologische Onkologie – Bewährtes und Vielversprechendes in der systemischen Therapie

Genitourinary oncology – Standards and developments in systemic therapy
Joachim H Hartlapp
1   Paracelsus-Klinik Golzheim, Düsseldorf
› Author Affiliations
Further Information

Publication History

Publication Date:
24 November 2014 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die systemische Therapie urologischer Tumore entwickelte sich für die unterschiedlichen Tumorentitäten in sehr unterschiedlicher Geschwindigkeit. So ist zum Beispiel beim Hodentumor die PEB-Kombination seit über 30 Jahren Standardchemotherapie geblieben, während beim weitgehend chemotherapieresistenten Nierenzellkarzinom erst in den letzten Jahren mit der Angiogenese-Blockade durch unterschiedliche Wirkstoffe eine effektive Therapie entwickelt werden konnte. Auch beim Prostatakarzinom setzt derzeit eine rasante Weiterentwicklung der Therapieoptionen ein, mit klassischen Zytostatika, neu entwickelten hormonell blockierenden Wirkstoffen und nuklearmedizinischen Therapieverfahren. Beim Harnblasenkarzinom, dem zweithäufigsten urologischen Tumor herrscht weitgehender Stillstand in der Neuentwicklung wirksamer Therapieoptionen, die in den letzten Jahren nur um eine einzige Substanz erweitert werden konnte. Für das seltene Peniskarzinom gibt es überhaupt noch keine evidenzbasiert gesicherte systemische Therapie.

Summary

Systemic therapy of genitourinary cancers has developed at different speed for the different tumor entities. For example in testicular cancer PEB combination chemotherapy has been standard for over 30 years, whereas in widely chemo-resistant renal cell carcinoma the inhibition of angiogenesis with different drugs has lead to the development of effective therapies over the last years. Currently also in prostate cancer rapid improvements in therapy options including new classical cytotoxic drugs, anti-hormonal substances and new approaches in nuclear medicine have occurred. In bladder cancer the second most common genitourinary tumor there is almost a standstill in the development of new therapy options with only one new substance added to the portfolio in recent years. For the rare penile carcinoma there is not yet an evidence based systemic therapy available at all.

Key words

Prostate - urinary bladder - kidneys - testes - penis
 

  • Literatur

  • 1 Sweeney C. Impact on survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate ( mPrCa): An ECOG-led phase III randomized trial. ASCO Annual Meeting, LBA 2, ASCO Daily News, Sunday June 1 2014, 8D
    PubMedGoogle Scholar
  • 2 Garcia-Albeniz X. Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. J Clin Oncol 2014; 32 (suppl: abstr. 5003)
    PubMedGoogle Scholar
  • 3 De Santis M. Feasibility and activity of two vinflunine (VFL)-based combinations as first-line chemotherapy (CT) in CDDP-unfit patients (pts) with advanced urothelial carcinoma (UC): VFL-gemcitabine (GEM) or VFL-CBDA in a randomized international phase II trial (JASINT). J Clin Oncol 2014; 32 (suppl: abstr. 4534)
    PubMedGoogle Scholar
  • 4 Galsky MD. Comparative effectiveness of gemcitabine plus cisplatin (GC) versus methotrexate, vinblastine, doxorubicin, plus cisplatin (MVAC) as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC). J Clin Oncol 2014; 32 (suppl: abstr. 4512)
    PubMedGoogle Scholar
  • 5 Sternberg CN. Final results of EORTC intergroup randomized phase III trial comparing immediate versus deferred chemotherapy after radical cystectomy in patients with pT3T4 and/or N+ M0 transitional cell carcinoma (TCC) of the bladder. J Clin Oncol 2014; 32 (suppl: abstr. 4500)
    PubMedGoogle Scholar
  • 6 Michel MS. SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafinib (SO)/ sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC). Proceedings Genitourinary Cancer Symposium, 2014, abstr 393
    PubMedGoogle Scholar
  • 7 Motzer RJ. Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN versus second-line EVE in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2013; 31 (suppl: abstr. 4504)
    PubMedGoogle Scholar
  • 8 Rini B, Escudier B, Tomczak P et al. Comparative effectiveness of axitinib versus sorafinib in advanced renal carcinoma (Axis): A randomized phase three trial. Lancet 2011; 378: 1931-1939
    CrossrefPubMedGoogle Scholar
  • 9 Fizazi K, Lance C, Pagliaro A et al. A phase III trial of personalized chemotherapy based on serum tumor marker decline in poor-prognosis germ-cell tumors: Results of GETUG 13. J Clin Oncol 2013; 31 (suppl: abstr. LBA 4500)
    PubMedGoogle Scholar
  • 10 Lorch A, Bascoul-Mollevi C, Kramar A et al. Conventional-Dose Versus High-Dose Chemotherapy As First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International Database. J Clin Oncol 2011; 29: 2178-2184
    CrossrefPubMedGoogle Scholar
  • 11 Pizzocaro G, Algaba F, Solsona E. Guidelines on Penile Cancer.. European Association of Urology 2013; 78-88
    PubMedGoogle Scholar
  • 12 Pizzocaro G, Piva L, Bandieramonte G et al. Up-to-date management of carcinoma of the penis. Eur Urol 1997; 32: 5-15
    PubMedGoogle Scholar
  • 13 Pizzocaro G, Nicolai N, Milani A. Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results. Eur Urol 2009; 55: 546-551
    CrossrefPubMedGoogle Scholar